Generic Name

Mycophenolate Mofetil

Brand Names
CellCept, Myhibbin
FDA approval date: May 03, 1995
Classification: Antimetabolite Immunosuppressant
Form: Injection, Tablet, Powder, Suspension, Capsule

What is CellCept (Mycophenolate Mofetil)?

CELLCEPT [mycophenolate mofetil ] is indicated for the prophylaxis of organ rejection, in recipients of allogeneic kidney [see Clinical Studies (1.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Background: Allogeneic blood or marrow transplant is when stem cells are taken from one person s blood or bone marrow and given to another person. Researchers think this may help people with immune system problems.

Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases

Summary: This phase I/II trial studies the best dose of total body irradiation with astatine-211 BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases undergoing hematopoietic cell transplant. Radiation therapy uses high energy gamma rays to kill cancer cells and shrink tumors. Astatine-211-labeled BC8-B10 monoclonal antibody is a monoclonal antibody, called anti-CD45 monoclo...

Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45)

Summary: This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment w...

Brand Information